Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

United States Embolic Protection Device Market is expected to reach US$ 650 million by 2033 from US$ 360 million in 2024, with a CAGR of 6.96% from 2025 to 2033. Rising cardiovascular operations, ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, ...

CHICAGO, IL—Cerebral embolic protection devices are infrequently used during transcatheter aortic valve implantation procedures in the United States, and new data suggest their use does not appear to ...

LONDON — Two years after the large multinational PROTECTED TAVR trial failed to associate a cerebral embolic protection (CEP) device with significant protection from stroke in patients undergoing ...

ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...

Higher TAVI procedure volumes are associated with a greater likelihood of using an embolic protection device, data from more than 500 US hospitals show. The authors undertook the study expecting to ...

The Sentinel cerebral embolic protection (CEP) device failed to reduce the overall stroke rate in patients undergoing transcatheter aortic valve replacement (TAVR) in the largest TAVR trial to date, ...

The recall was initiated following reports of 9 device malfunctions. Cardiovascular Systems Inc. has issued a voluntary recall of unused WIRION ® Embolic Protection systems due to complaints of filter ...

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI ®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...